Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor

Pharmacology Research and Perspectives

Volumn 3, Issue 1, 2015, Pages 1-15

  Lavreysen, Hilde ^a   Ahnaou, Abdellah ^a   Drinkenburg, Wilhelmus ^a   Langlois, Xavier ^a   Mackie, Claire ^a   Pype, Stefan ^a   Lütjens, Robert ^b   Le Poul, Emmanuel ^b   Trabanco, Andrés A ^a   Nuñez, José María Cid ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Addex Therapeutics Plan les Ouates Switzerland   (Switzerland)

Author keywords

In vitro; JNJ 40411813; MGlu2 PAM; Occupancy; Pharmacokinetics; Sleep wake EEG

Indexed keywords

1 BUTYL 3 CHLORO 4 (4 PHENYL 1 PIPERIDINYL) 2(1H) PYRIDINONE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AZD 8529; GLUTAMIC ACID; JNJ 40411813; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG SELECTIVITY; EC50; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; FRONTAL CORTEX; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RECEPTOR BINDING ASSAY; SINGLE DRUG DOSE; SLEEP WAKING CYCLE; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 85007152183     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.96     Document Type: Article

References (43)

1. Ackermann S, Rasch B (2014). Differential effects of non-REM and REM sleep on memory consolidation? Curr Neurol Neurosci Rep 14: 430-440.
2. Ahnaou A, Dautzenberg FM, Geys H, Imogai H, Gibelin A, Moechars D, et al. (2009). Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol 603: 62-72.
3. Cartmell J, Monn JA, Schoepp DD (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170.
4. De Boer P, Sinha V, Hoeben E, Anghelescu I-G, Kezic I, Daly E, et al. (2013). Characterization of the clinical effect of a positive allosteric modulator of the metabotropic glutamate receptor 2. 68th Annual Scientific Convention of Society of Biological Psychiatry 73 (Supplement, Issue 9): A1-A8, 1S-344S.
5. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD (2008). Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33: 1603-1610.
6. Fell MJ, Svensson KA, Johnson BG, Schoepp DD (2008). Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 326: 209-217.
7. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, et al. (2011). N-(4-((2 (trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methy l-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336: 165-177.
8. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005). A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315: 1181-1187.
9. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al. (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318: 173-185.
10. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158(9): 1367-77.
11. Hoeben E, Sinha V, de Boer P, Wuyts K, Bohets H, Scheers E, et al. (2013). Prediction of Serotonin 2A Receptor (5-HT2AR) Occupancy in Man From Nonclinical Pharmacology Data. Exposure vs. 5-HT2AR Occupancy Modeling Used to Help Design a Positron Emission Tomography (PET) Study in Healthy Male Subjects. 22nd Annual Population Approach Group Europe (PAGE) Meeting, 11-14 June 2013, Glasgow, UK.
12. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD (2005). Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179(1): 271-83.
13. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD (2003). Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2, 2, 2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46(15): 3189-92.
14. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al. (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318: 173-185.
15. Kent J, Anghelescu I, Kezic I, Daly E, Ceusters M, De Smedt H, et al. (2013). Safety, tolerability and potential therapeutic efficacy of a novel glutamate modulator as adjunctive treatment in patients with schizophrenia. Presented at the 166th Annual Meeting of the American Psychiatric Association, 18-22 May 2013, San Francisco, CA.
16. Kent JM, Daly E, Ceusters M, Kezic I, Lane R, Lim P, et al. (2014). Efficacy and safety of a novel mglu2 receptor positive allosteric modulator as an adjunctive treatment to an SSRI/SNRI in the treatment of anxious depression. Presented at 8th International meeting on metabotropic glutamate receptors, 28 September -3 October, 2014, Taormina, Italy.
17. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. (2011). A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31: 349-355.
18. Kodama T, Lai YY, Siegel JM (1998). Enhanced glutamate release during REM sleep in the rostromedial medulla as measured by in vivo microdialysis. Brain Res 780: 178-181.
19. Lavreysen H, Langlois X, Ahnaou A, Drinkenburg W, te Riele P, Biesmans I, et al. (2013). Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther 346: 514-527.
20. Lavreysen H, Langlois X, Ver Donck L, Cid J, Pype S, Megens A (submitted). Preclinical evaluation of the antipsychotic potential of the mGlu2-PAM JNJ-40411813. Pharmacol Res Perspect DOI: 10.1002/prp2.97.
21. Marsman A, Mandl RC, van den Heuvel MP, Boer VO, "Wijnen JP, Klomp DW, Luijten PR, Hilleke E HP, (2013). Glutamate changes in healthy young adulthood. Eur Neuropsychopharmacol 23(11): 1484-90.
22. Litman RE, Smith MA, Doherty J, Cross A, Raines S, Zukin S (2014). AZD8529, a positive allosteric modulator at the MGLUR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study. Presented at NCDEU an Annual meeting of ASCP, 16-19 June 2014, Florida.
23. Lopez-Rodriguez F, Medina-Ceja L, Wilson CL, Jhung D, Morales-Villagran A (2007). Changes in extracellular glutamate levels in rat orbitofrontal cortex during sleep and wakefulness. Arch Med Res 38: 52-55.
24. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H (2010). Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77: 317-326.
25. Mezler M, Geneste H, Gault L, Marek GJ (2010). LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs 11: 833-845.
26. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
27. Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS (2008). Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 31: 34-44.
28. Niswender CM, Conn PJ (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295-322.
29. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13: 1102-1107.
30. Rasch B, Pommer J, Diekelmann S, Born J (2009). Pharmacological REM sleep suppression paradoxically improves rather than impairs skill memory. Nat Neurosci 12: 296-297.
31. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E (2012). New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 100: 752-774.
32. te Riele P, Biesmans I, Peeters L, Lavreysen H, Langlois X. Characterization of the mGlu2 PAM radioligand[3H]JNJ-46281222and its application for ex vivo receptor occupancy in rat brain. Poster presented at 8th international meeting on metabotropic glutamate receptors, Taormina, Sicily Italy, Sept 30, 2014.
33. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, et al. (2007). In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193: 121-136.
34. Sanacora G, Treccani G, Popoli M (2012). Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62: 63-77.
35. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ (2003). LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6: 189-197.
36. Siok CJ, Cogan SM, Shifflett LB, Doran AC, Kocsis B, Hajos M (2012). Comparative analysis of the neurophysiological profile of group II metabotropic glutamate receptor activators and diazepam: effects on hippocampal and cortical EEG patterns in rats. Neuropharmacology 62: 226-236.
37. Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. (2013). Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophrenia Res 150: 434-441.
38. 3H]JNJ-46281222 and its application for ex vivo receptor occupancy in rat brain. 8th International meeting on metabotropic glutamate receptors, 28 September - 3 October 2014, Taormina, Italy.
39. Trabanco AA, Cid JM (2013). mGluR2 positive allosteric modulators: a patent review (2009 - present). Expert Opin Ther Pat 23: 629-647.
40. Trabanco AA, Cid JM, Lavreysen H, Macdonald GJ, Tresadern G (2011). Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2. Curr Med Chem 18: 47-68.
41. Vanover KE, Davis RE (2010). Role of 5HT2A receptor antagonists in the treatment of insomnia. Nat Sci Sleep 2: 139-150.
42. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN (2008). The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196: 431-440.
43. Zisapel N (2012). Drugs for insomnia. Expert Opin Emerg Drugs 17: 299-317.